Vanguard Group Inc. Sells 58,957 Shares of Omnicell, Inc. $OMCL

Vanguard Group Inc. decreased its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 1.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 5,553,044 shares of the company’s stock after selling 58,957 shares during the period. Vanguard Group Inc. owned 0.12% of Omnicell worth $251,553,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new position in Omnicell during the third quarter valued at approximately $25,625,000. Two Sigma Investments LP lifted its stake in shares of Omnicell by 93.8% in the third quarter. Two Sigma Investments LP now owns 559,969 shares of the company’s stock worth $17,051,000 after buying an additional 271,008 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Omnicell by 9.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock worth $71,985,000 after buying an additional 197,462 shares during the period. Qube Research & Technologies Ltd grew its stake in Omnicell by 38.4% in the 2nd quarter. Qube Research & Technologies Ltd now owns 653,971 shares of the company’s stock valued at $19,227,000 after buying an additional 181,394 shares during the last quarter. Finally, UBS Group AG grew its stake in Omnicell by 145.0% in the 3rd quarter. UBS Group AG now owns 276,286 shares of the company’s stock valued at $8,413,000 after buying an additional 163,499 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Corey J. Manley sold 7,405 shares of Omnicell stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $34.69, for a total transaction of $256,879.45. Following the sale, the executive vice president directly owned 96,717 shares of the company’s stock, valued at $3,355,112.73. This trade represents a 7.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.92% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on OMCL shares. Benchmark reissued a “buy” rating on shares of Omnicell in a research report on Friday, March 13th. Wall Street Zen raised Omnicell from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Wells Fargo & Company raised their price target on Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a research report on Thursday, April 23rd. Weiss Ratings raised Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday. Finally, Zacks Research raised Omnicell from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $59.86.

Omnicell Stock Up 1.1%

OMCL stock opened at $43.82 on Friday. Omnicell, Inc. has a twelve month low of $25.44 and a twelve month high of $55.00. The company has a market cap of $1.99 billion, a PE ratio of 99.59, a price-to-earnings-growth ratio of 1.09 and a beta of 0.96. The business’s 50-day simple moving average is $37.38 and its 200 day simple moving average is $39.87. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last released its earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The business had revenue of $309.88 million for the quarter, compared to the consensus estimate of $304.02 million. During the same period last year, the business earned $0.26 earnings per share. The firm’s revenue for the quarter was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. On average, research analysts anticipate that Omnicell, Inc. will post 1.34 earnings per share for the current year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.